CareDx (NASDAQ:CDNA) Hits New 52-Week High at $15.30

Shares of CareDx, Inc (NASDAQ:CDNA - Get Free Report) reached a new 52-week high on Friday . The stock traded as high as $15.30 and last traded at $14.19, with a volume of 664434 shares traded. The stock had previously closed at $11.06.

Analysts Set New Price Targets

Several brokerages recently commented on CDNA. Craig Hallum restated a "buy" rating and set a $15.00 target price on shares of CareDx in a research report on Thursday. Stephens reaffirmed an "overweight" rating and set a $15.00 price objective on shares of CareDx in a research report on Wednesday, April 17th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $14.00.

CareDx Trading Up 34.1 %

The business has a 50-day moving average of $9.79 and a 200 day moving average of $9.52. The firm has a market capitalization of $767.88 million, a P/E ratio of -4.19 and a beta of 1.51.

CareDx (NASDAQ:CDNA - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($2.21) EPS for the quarter, missing the consensus estimate of ($0.24) by ($1.97). CareDx had a negative net margin of 67.88% and a negative return on equity of 51.40%. The firm had revenue of $65.57 million for the quarter, compared to the consensus estimate of $63.66 million. During the same quarter in the prior year, the firm earned ($0.34) EPS. The company's revenue was down 20.4% compared to the same quarter last year. As a group, research analysts forecast that CareDx, Inc will post -1.59 EPS for the current year.

Institutional Trading of CareDx

Institutional investors and hedge funds have recently modified their holdings of the stock. Headlands Technologies LLC purchased a new position in CareDx in the fourth quarter worth $50,000. Nisa Investment Advisors LLC raised its position in shares of CareDx by 442.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,440 shares of the company's stock valued at $77,000 after purchasing an additional 5,253 shares during the period. Quest Partners LLC purchased a new stake in shares of CareDx during the 4th quarter valued at approximately $117,000. WINTON GROUP Ltd bought a new position in CareDx in the 3rd quarter worth approximately $72,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in CareDx by 23.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,751 shares of the company's stock valued at $82,000 after buying an additional 2,211 shares in the last quarter.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.